Moderna Lowers 2025 Revenue Forecast but Beats Q3 Expectations
Moderna cut its 2025 revenue forecast due to weak U.S. COVID-19 vaccine sales but beat Wall Street’s Q3 estimates, lifting shares premarket.
/ 919 items
#Healthcare↓
Oscar Health Posts $137M Q3 Loss But Eyes 2026 Profitability Return
Oscar Health reports third quarter loss amid rising healthcare costs but plans return to profitability in 2026 through rate increases and market expansion in ACA insurance space.
FTC Warns Novo Nordisk Over Potential Violation in Metsera Bid
The U.S. Federal Trade Commission cautioned Novo Nordisk that its proposed acquisition of Metsera may breach premerger review laws under the Hart-Scott-Rodino Act.
FDA Greenlights Linaclotide (Linzess) for Children 7 Years and Older with Irritable Bowel Syndrome with Constipation
Ironwood's Linzess is the first FDA-approved drug for children 7+ with IBS-C (chronic constipation, pain, and bloating).
Orexin Drug Race: Centessa Shows Promise, Alkermes Stands Strong
Centessa has great sleep drug data, easing daytime sleepiness. Alkermes stock jumped 7% as its competing drug is still strong.
Pharma Stock Moves: Oppenheimer Downgrades Rhythm, New Buys on Vanda, Verrica, CervoMed, and Ventyx
Oppenheimer downgrades Rhythm Pharmaceuticals after major gains, while analysts issue fresh Buy ratings on Vanda, Verrica, CervoMed, and Ventyx highlighting key catalysts and growth potential.